Moleculin Provides Update on Annamycin Clinical Development
HOUSTON, July 2, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced an update on its clinical...
New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model
Findings published in Clinical Cancer ResearchHOUSTON, July 1, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and...
Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
Data Presented at the AACR Annual MeetingHOUSTON, June 25, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,...
Moleculin to Present at the Life Sciences Investor Forum
HOUSTON, June 23, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief...
Moleculin Announces Confirmatory In Vitro Analysis of WP1122
Receives feedback from FDA on Pre-IND meetingHOUSTON, June 16, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous...
Moleculin Announces Submission to Expand Clinical Sites in European AML Trial
Submits regulatory requests to open two additional clinical sites in PolandHOUSTON, June 4, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today...
Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment
Pediatric trial marks the second brain tumor trial of Moleculin's lead STAT3 inhibitorHOUSTON, June 2, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates,...
Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020
HOUSTON, May 27, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received...
Moleculin Provides Update on Coronavirus Drug Development
FDA grants Pre-IND Meeting requestHOUSTON, May 27, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information
HOUSTON, May 18, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that pending the receipt...